Table 2.
Artemether-lumefantrine efficacy in children in Brazzaville.
| Number | Percentage | 95% CI | |
|---|---|---|---|
| No. of patients | 77 | ||
| Responses on day 14 | |||
| Withdrawn or loss to follow up | 4 | 5.2 | 1.4–12.8 |
| Eligible | 73 | 94.8 | 87.2–98.6 |
| ETF | 1 | 1.4 | 0–7.4 |
| ACPR | 72 | 98.6 | 92.6–100 |
| Responses on day 28 (PCR uncorrected) | |||
| Withdrawn or loss to follow up | 8 | 10.4 | 4.6–19.4 |
| Eligible | 69 | 89.6 | 80.6–95.4 |
| Treatment failure | 7 | 11.3 | 4.2–19.8 |
| ETF | 1 | 1.5 | 0.05–7.8 |
| LCF | 2 | 2.9 | 0.4–10.1 |
| LPF | 4 | 5.5 | 1.6–14.2 |
| ACPR† | 62 | 89.9 | 80.2–95.8 |
| Responses on day 28 (PCR corrected) | |||
| Withdrawn or loss to follow up | 8 | 16.9 | 9.3–27.1 |
| Eligible | 69 | 86.6 | 80.6–5.4 |
| Treatment failure | 2 | 2.9 | 0.4–10.0 |
| ETF | 1 | 1.4 | 0.04–7.8 |
| Recrudescence | 1 | 1.4 | 0.04–7.8 |
| ACPR‡ | 67 | 97.1 | 89.9–99.6 |
| PCR analysed isolates | |||
| Recrudescence | 1 | 16.7 | 0.4–64.1 |
| Reinfection | 5 | 83.3 | 35.9–99.6 |
95% CI: 95% confidence intervals; ETF: early treatment failure; LCF: late clinical failure; LPF: late parasitological failure; ACPR: adequate clinical and parasitological response.
†Of these patients, 86.5% (95% CI, 71.2–95.5%) under 5 years old had ACPR response, while 93.8% (95% CI, 79.2–99.2%) of the patients aged between 5 and 10 years old responded with ACPR. The difference in ACPR proportions between these two subpopulations of patients was not significant (P = 0.6, chi-square test).
‡Of the patients responding with ACPR, 94.1% (95% CI, 80.3–99.3%) were aged <5 years old and 100% (95% CI, 88.4–100%) were aged between 5 and 10 years old. The difference in ACPR proportions between the two subpopulations of patients was not significant (P = 0.5, chi-square test).